HANGZHOU, China, July 30, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2024.
Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased to present our financial performance for fiscal year 2024, which reflects our commitment to maintaining a resilient business model in a dynamic market. We achieved a significant 42.1% revenue growth in our wholesale business, a result of our dedicated efforts in targeting wholesale buyers with competitively priced product offerings, and leveraging modern wholesale platforms to boost sales. We believe this strategy will benefit us for long-term and sustainable growth. Our dedication to high-quality services and products remains strong. By adopting agile product and pricing strategies, we have successfully navigated a competitive landscape in China's healthcare market. Looking ahead, we will keep strengthening our competitive advantages to differentiate our business and deliver outstanding results. We plan to actively seek as great growth potential opportunities as possible to strengthen our business, improve our customer experience, and expand our product portfolio to meet evolving customer needs. We will also continue to seize opportunities to facilitate market expansion and remain focused on gaining efficiencies and controlling costs to achieve the accelerated growth. We are deeply committed to contributing to China's healthcare market and communities we support, and we will continue to create greater value for our shareholders, ensuring that our contributions benefit all our shareholders."
Fiscal Year 2024 Financial Highlights | ||||||
For the Year Ended March 31, | ||||||
($ millions, except per share data) | 2024 | 2023 | % Change | |||
Revenue | 154.54 | 148.81 | 3.8 % | |||
Retail drugstores | 75.68 | 83.35 | (9.2) % | |||
Online pharmacy | 31.86 | 32.38 | (1.6) % | |||
Wholesale | 47.00 | 33.08 | 42.1 % | |||
Gross profit | 31.11 | 34.28 | (9.3) % | |||
Gross margin | 20.1 % | 23.0 % | (2.9)pp | |||
Loss from operations | (3.53) | (20.93) | 83.1 % | |||
Net loss | (4.23) | (21.14) | 80.0 % | |||
Loss per share | (2.93) | (41.46) | 92.9 % | |||
*Notes: pp represents percentage points | ||||||
Fiscal Year 2024 Financial Results
Revenue
Revenue increased by $5.73 million, or 3.8%, to $154.54 million for the fiscal year ended March 31, 2024, from $148.81 million for the same period of last year.
For the Year Ended March 31, | ||||||||||||
2024 | 2023 | |||||||||||
($ millions) | Revenue | Cost of | Average | Revenue | Cost of | Average | ||||||
Retail drugstores | 75.68 | 53.06 | 29.9 % | 83.35 | 56.55 | 32.2 % | ||||||
Online pharmacy | 31.86 | 28.24 | 11.3 % | 32.38 | 28.51 | 12.0 % | ||||||
Wholesale | 47.00 | 42.13 | 10.4 % | 33.08 | 29.47 | 10.9 % | ||||||
Total | 154.54 | 123.43 | 20.1 % | 148.81 | 114.53 | 23.0 % | ||||||
Revenue from the retail drugstores business decreased by $7.67 million, or 9.2%, to $75.68 million for the fiscal year ended March 31, 2024, from $83.35 million for the same period of last year. After excluding the impact of exchange rate fluctuation, the actual retail drugstores sales decreased by 5.0%. The decrease in its retail drugstore sales is primarily due to local consumption cutback, extremely competitive market and the temporary surge of sale in the second half of fiscal 2023, which is nonrecurring and is due to Chinese government's sanction lift on COVID-19.
Revenue from the online pharmacy business decreased by $0.53 million, or 1.6%, to $31.86 million for the fiscal year ended March 31, 2024, from $32.38 million for the same period of last year. The decrease was primarily caused by a decrease in sales via e-commerce platforms such as JD and Pinduoduo. Because the online prices are transparent, to be competitive in online sales, the Company has to keep low prices. More competitors came into the online retail sales market. As the Company does not have dominating power such as lowest prices or exclusive products, it may not be able to improve its sales significantly in the near future.
Revenue from the wholesale business increased by $13.93 million, or 42.1%, to $47.00 million for the fiscal year ended March 31, 2024, from $33.08 million for the same period of last year. In the year ended March 31, 2024, Online platforms such as Pharmacist Help, Yiyao Help and Yao Help have become popular ways to transact medical products by bulk. The platforms attract a plenty of buyers and sellers, so both parties have extended opportunities to expose themselves. The Company has spent significant efforts in exploring these buyers with certain products at reasonable prices as a result, the Company is able to attract more buyers and promote its sales. The Company believes that selling on the modern wholesale platform may be a new growth point. Therefore, the Company is actively looking for potential acquisition targets with trading platform to strengthen its wholesale business.
Gross profit and gross margin
Total cost of goods sold increased by $8.90 million, or 7.8%, to $123.43 million for the fiscal year ended March 31, 2024, from $114.53 million for the same period of last year. Gross profit decreased by $3.17 million, or 9.3%, to $31.11 million for the fiscal year ended March 31, 2024 from $34.28 million for the same period of last year. Overall gross margin decreased by 2.9 percentage points to 20.1% for the fiscal year ended March 31, 2024, from 23.0% for the same period of last year, due to lower retail drugstores profit margins.
Gross margins for retail drugstores, online pharmacy and wholesale were 29.9%, 11.3%, and 10.4%, respectively, for the fiscal year ended March 31, 2024, compared to gross margins for retail drugstores, online pharmacy and wholesale of 32.2%, 12.0%, and 10.9%, respectively, for the same period of last year.
Loss from operations
Sales and marketing expenses decreased by $1.79 million, or 6.1%, to $27.39 million for the fiscal year ended March 31, 2024 from $29.18 million for the same period of last year. The decrease in selling expenses was primarily due to a decrease in expense related to Normal Nucleic Acid Testing ("NNAT") as it is no longer requested by local government and a decrease in fee charged by distribution channels resulting from the decrease in retail drugstores and online pharmacy sales.
General and administrative expenses decreased by $8.41 million, or 53.7%, to $7.26 million for the fiscal year ended March 31, 2024 from $15.67 million for the same period of last year. The decrease in general and administrative expenses was primarily due to the decrease in bad debt expense. Such expenses as a percentage of revenue decreased to 4.7% from 10.5% for the same period a year ago. In the year ended March 31, 2024, the Company recorded a reduction of $0.22 million in the allowance account for bad debts as compared to the increase of $7.58 million in the allowance account for bad debts in FY2023.
Loss from operations was $3.53 million for the fiscal year ended March 31, 2024, compared to $20.93 million for the same period of last year. Operating margin was (2.3)% and (14.1)% for the fiscal year ended March 31, 2024 and 2023, respectively.
Net loss
Net loss was $4.23 million, or $2.93 per basic and diluted share for the fiscal year ended March 31, 2024, compared to net loss of $21.14 million, or $41.46 per basic and diluted share for the same period of last year.
Financial Condition
As of March 31, 2024, the Company had cash of $20.15 million, compared to $18.81 million as of March 31, 2023. Net cash used in operating activities was $3.16 million for the fiscal year ended March 31, 2024, compared to $3.28 million for the same period of last year. The change is primarily attributable to an increase in net income of $16.90 million, an increase in accounts receivable of $0.73 million, an increase in cash provided by accounts payable of $4.24 million and an increase in cash provided by other payables and accrued liabilities of $2.21 million, offset by a decrease in bad debt direct write-off and provision of $6.79 million, a decrease in inventories and biological assets of $1.18 million and a decrease in stock compensation of $10.36 million. Net cash used in investing activities was $2.04 million for the fiscal year ended March 31, 2024, compared to $0.32 million for the same period of last year. The change is primarily attributable to investment in a joint venture and purchases of long-term assets. Net cash provided by financing activities was $8.00 million for the fiscal year ended March 31, 2024, compared to $2.37 million for the same period of last year. The change is primarily due to notes payable and proceeds from short-term bank loan.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Company Contact:
Frank Zhao
Chief Financial Officer
+86-571-88077108
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Tina Xiao
Ascent Investor Relations LLC
+1-646-932-7242
This email address is being protected from spambots. You need JavaScript enabled to view it.
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES | ||||||
March 31, | March 31, | |||||
ASSETS | ||||||
CURRENT ASSETS | ||||||
Cash and cash equivalents | $ | 20,149,806 | $ | 18,807,936 | ||
Restricted cash | 12,724,365 | 12,762,708 | ||||
Trade accounts receivables | 15,824,103 | 14,119,606 | ||||
Inventories | 16,248,373 | 15,309,100 | ||||
Other receivables, net | 2,938,049 | 2,725,015 | ||||
Advances to suppliers | 914,776 | 142,417 | ||||
Due from related parties | 313,346 | - | ||||
Other current assets | 569,544 | 616,008 | ||||
Total current assets | 69,682,362 | 64,482,790 | ||||
OTHER ASSETS | ||||||
Property and equipment, net | 4,906,589 | 5,100,264 | ||||
Long-term investment | 1,195,261 | 1,772,072 | ||||
Farmland assets | 634,153 | 666,721 | ||||
Long-term deposits | 1,119,006 | 1,038,125 | ||||
Other noncurrent assets | 682,437 | 790,056 | ||||
Operating lease right-of-use assets | 13,827,360 | 13,924,826 | ||||
Intangible assets, net | 3,009,922 | 3,195,748 | ||||
Total other assets | 25,374,728 | 26,487,812 | ||||
Total assets | $ | 95,057,090 | $ | 90,970,602 | ||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES | ||||||
Short-term loan payable | $ | 276,997 | $ | - | ||
Accounts payable | 31,630,131 | 26,990,250 | ||||
Notes payable | 31,676,335 | 29,255,776 | ||||
Other payables | 2,493,482 | 1,314,919 | ||||
Due to related parties | 1,833,509 | 683,560 | ||||
Customer deposits | 518,241 | 695,931 | ||||
Taxes payable | 682,239 | 1,706,909 | ||||
Accrued liabilities | 386,395 | 756,516 | ||||
Current portion of operating lease liabilities | 4,862,766 | 5,131,373 | ||||
Total current liabilities | 74,360,095 | 66,535,234 | ||||
Long-term operating lease liabilities | 6,403,858 | 7,768,216 | ||||
Total liabilities | 80,763,953 | 74,303,450 | ||||
COMMITMENTS AND CONTINGENCIES | ||||||
SHAREHOLDERS' EQUITY | ||||||
Ordinary shares; $0.24 par value; 150,000,000 shares authorized; 1,743,362 and | 418,407 | 284,367 | ||||
Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and | - | - | ||||
Additional paid-in capital | 86,413,978 | 83,958,418 | ||||
Statutory reserves | 1,309,109 | 1,309,109 | ||||
Accumulated deficit | (73,507,246) | (69,273,018) | ||||
Accumulated other comprehensive income | 1,005,762 | 1,735,135 | ||||
Total shareholders' equity attributed to China Jo-Jo | 15,640,010 | 18,014,011 | ||||
Noncontrolling interests | (1,346,873) | (1,346,859) | ||||
Total shareholders' equity | 14,293,137 | 16,667,152 | ||||
Total liabilities and shareholders' equity | $ | 95,057,090 | $ | 90,970,602 | ||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES | ||||||||
For the years ended | ||||||||
2024 | 2023 | 2022 | ||||||
REVENUES, NET | $ | 154,541,077 | $ | 148,811,976 | $ | 164,392,555 | ||
COST OF GOODS SOLD | 123,432,529 | 114,531,512 | 127,873,515 | |||||
GROSS PROFIT | 31,108,548 | 34,280,464 | 36,519,040 | |||||
SELLING EXPENSES | 27,385,587 | 29,177,163 | 30,876,959 | |||||
GENERAL AND ADMINISTRATIVE EXPENSES | 7,257,524 | 15,668,684 | 8,187,176 | |||||
STOCK BASED COMPENSATION | - | 10,360,000 | - | |||||
IMPAIRMENT OF LONG-LIVED ASSETS | - | - | 148,795 | |||||
TOTAL OPERATING EXPENSES | 34,643,111 | 55,205,847 | 39,212,930 | |||||
LOSS FROM OPERATIONS | (3,534,563) | (20,925,383) | (2,693,890) | |||||
OTHER INCOME (EXPENSES): | ||||||||
INTEREST INCOME | 516,637 | 883,908 | 401,921 | |||||
INTEREST EXPENSE | (13,604) | (65,854) | (262,218) | |||||
INVESTMENT LOSS | (1,607,537) | (2,316,994) | - | |||||
OTHER INCOME (EXPENSES) | 467,687 | 1,680,087 | 455,547 | |||||
LOSS BEFORE INCOME TAXES | (4,171,380) | (20,744,236) | (2,098,640) | |||||
PROVISION FOR INCOME TAXES | 62,862 | 394,541 | 1,099,726 | |||||
NET LOSS | (4,234,242) | (21,138,777) | (3,198,366) | |||||
LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING | (14) | (252) | (6,247) | |||||
NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, | (4,234,228) | (21,138,525) | (3,192,119) | |||||
OTHER COMPREHENSIVE LOSS | ||||||||
FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | (729,373) | (2,617,857) | 1,534,807 | |||||
COMPREHENSIVE LOSS | (4,963,615) | (23,756,634) | (1,663,559) | |||||
WEIGHTED AVERAGE NUMBER OF SHARES: | ||||||||
Basic | 1,444,263 | 509,828 | 173,966 | |||||
Diluted | 1,444,263 | 509,828 | 173,966 | |||||
LOSS PER SHARE: | ||||||||
Basic | $ | (2.93) | $ | (41.46) | $ | (18.35) | ||
Diluted | $ | (2.93) | $ | (41.46) | $ | (18.35) | ||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES | ||||||||
For the years ended | ||||||||
2024 | 2023 | 2022 | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | $ | (4,234,242) | $ | (21,138,777) | $ | (3,198,366) | ||
Adjustments to reconcile net loss to net cash used in operating | ||||||||
Depreciation and amortization | 790,449 | 718,002 | 1,256,491 | |||||
Bad debt direct write-off and provision and reversal | (249,257) | 7,579,886 | 939,720 | |||||
Amortization of right-of-use assets | 4,594,172 | - | - | |||||
Loss from disposal of property and equipment | 107,251 | - | - | |||||
Impairment of long lived assets | - | - | 148,795 | |||||
Share-based compensation | - | 10,360,000 | - | |||||
Investment loss | 1,607,537 | 2,316,994 | - | |||||
Change in operating assets and liabilities: | ||||||||
Accounts receivable | (1,804,440) | (2,531,755) | (2,657,283) | |||||
Notes receivable | 19,943 | (20,861) | 40,260 | |||||
Inventories and biological assets | (1,699,621) | (522,550) | 1,523,098 | |||||
Other receivables | (672,830) | (958,671) | (1,927,692) | |||||
Advances to suppliers | (839,221) | 201,984 | (171,783) | |||||
Long term deposit | (132,568) | 589,653 | (159,508) | |||||
Other current assets | 19,076 | 331,426 | 376,134 | |||||
Other noncurrent assets | 69,539 | (30,483) | 62,394 | |||||
Amount due from related parties | (317,828) | - | - | |||||
Accounts payable | 6,002,186 | 1,765,488 | (3,558,050) | |||||
Other payables and accrued liabilities | 868,975 | (1,341,447) | 99,132 | |||||
Customer deposits | (144,761) | (1,035,456) | 678,601 | |||||
Taxes payable | (948,277) | 433,054 | 1,162,084 | |||||
Operating lease liabilities | (6,191,522) | - | - | |||||
Net cash used in operating activities | (3,155,439) | (3,283,513) | (5,385,973) | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Acquisition of equipment and building | (330,677) | (118,272) | (89,960) | |||||
Investment in a joint venture | (1,116,212) | (4,379) | - | |||||
Purchases of intangible assets | (66,973) | (12,774) | (7,012) | |||||
Additions to leasehold improvements | (525,988) | (180,672) | (209,166) | |||||
Net cash used in investing activities | (2,039,850) | (316,097) | (306,138) | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from short-term bank loan | 1,116,212 | - | - | |||||
Repayment of short-term bank loan | (837,159) | - | (779,059) | |||||
Repayment of third parties loan | - | (1,811,558) | (2,613,965) | |||||
Proceeds from notes payable | 56,875,403 | 57,965,013 | 65,370,181 | |||||
Repayment of notes payable | (52,997,171) | (60,273,598) | (57,829,269) | |||||
Proceeds from issuance of shares and warrants in private placements | 2,589,600 | 7,325,000 | - | |||||
Proceeds from other payable-related parties | 1,257,406 | 43,785 | 689,010 | |||||
Repayment of other payable-related parties | - | (882,486) | ||||||
Net cash provided by financing activities | 8,004,291 | 2,366,156 | 4,836,898 | |||||
EFFECT OF EXCHANGE RATE ON CASH | (1,505,475) | (2,535,479) | 1,522,146 | |||||
INCREASE IN CASH AND CASH EQUIVALENTS AND | 1,303,527 | (3,768,933) | 666,933 | |||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, | 31,570,644 | 35,339,577 | 34,672,644 | |||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end | $ | 32,874,171 | $ | 31,570,644 | $ | 35,339,577 | ||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW | ||||||||
Cash paid for income taxes | $ | 149,023 | $ | 63,668 | $ | 3,955 | ||
Cash paid for interest | 13,604 | 64,943 | 262,218 | |||||
NON-CASH ACTIVITIES： | ||||||||
Cashless exercise of warrants | $ | - | $ | 135,118 | $ | - | ||
| Last Trade: | US$1.85 |
| Daily Change: | -0.18 -8.87 |
| Daily Volume: | 3,514 |
| Market Cap: | US$12.300M |
September 26, 2023 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
